Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469907 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04469907 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 18 participants.
The verdict
NCT04469907, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up will be approximately 5 weeks.
Interventions
- DRUG AZD9977
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04469907
The ClinicalTrials.gov registry entry for NCT04469907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD9977 is the first listed.
NCT04469907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04469907 about?
NCT04469907 is a clinical study titled "Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment". This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up wil...
What is the current status of trial NCT04469907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-06-22. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT04469907?
The interventions under investigation include: AZD9977 (DRUG).
Who is sponsoring clinical trial NCT04469907?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.